| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C24H29N |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
BChE-IN-14 is a selective inhibitor of butyrylcholinesterase (BChE), with IC50 values of 0.23 μM for equine BChE and 0.011 μM for human BChE. It shows good blood-brain barrier permeation and primary cell safety, and it restores cognitive impairment in vivo, and can be used in Alzheimer's disease research[1]. Its molecular formula is C24H29N, with a molecular weight of 331.49 g/mol.
Physical & Chemical Properties
| CAS Number | 2700896-78-0 |
|---|---|
| Molecular Formula | C24H29N |
| Molecular Weight | 331.49 g/mol |
| SMILES | CCCCN(CC1=CC=C2C=CC=CC2=C1)CCCC3=CC=CC=C3 |
| Signaling Pathway | Neuronal Signaling |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 0.23 μM (eqBChE), 0.011 μM (hBChE)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Lu X, et al. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem. 2022 Sep 2;243:114729.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
BChE-IN-14 (0.0001-100 μM) inhibits eqBChE from horse serum and hBChE, with IC50s of 0.23 and 0.011 μM, respectively[1].
In Vivo
BChE-IN-14, given p.o. at 15 mg/kg on Aβ1-42 injection days 3-8, affects memory and cognitive function in an AD mouse model[1].
| Animal Model | ICR mice with oligomerized Aβ1-42 peptide injection[1] |
|---|---|
| Dosage | 15 mg/kg |
| Administration | Oral gavage; 15 mg/kg for Aβ1-42 injection days 3-8 |
| Result | Improved memory and cognitive function in vivo and showed a shorter latency than donepezil. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
